C WorldWide Group Holding A S Purchases Shares of 250,000 Alkermes plc (NASDAQ:ALKS)

C WorldWide Group Holding A S purchased a new stake in shares of Alkermes plc (NASDAQ:ALKS) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 250,000 shares of the company’s stock, valued at approximately $7,190,000. C WorldWide Group Holding A S owned 0.15% of Alkermes as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Venturi Wealth Management LLC bought a new stake in Alkermes during the fourth quarter valued at about $25,000. Blue Trust Inc. increased its holdings in shares of Alkermes by 2,231.5% in the fourth quarter. Blue Trust Inc. now owns 1,702 shares of the company’s stock worth $49,000 after purchasing an additional 1,629 shares during the last quarter. Archer Investment Corp increased its holdings in shares of Alkermes by 28.6% in the third quarter. Archer Investment Corp now owns 4,500 shares of the company’s stock worth $126,000 after purchasing an additional 1,000 shares during the last quarter. KBC Group NV increased its holdings in shares of Alkermes by 18.8% in the third quarter. KBC Group NV now owns 4,890 shares of the company’s stock worth $137,000 after purchasing an additional 774 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Alkermes by 17.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,956 shares of the company’s stock worth $164,000 after purchasing an additional 904 shares during the last quarter. 95.21% of the stock is owned by institutional investors.

Alkermes Price Performance

Shares of NASDAQ:ALKS opened at $35.33 on Monday. Alkermes plc has a 1 year low of $22.90 and a 1 year high of $36.45. The business has a 50 day simple moving average of $30.89 and a two-hundred day simple moving average of $29.08. The firm has a market capitalization of $5.74 billion, a PE ratio of 16.28, a price-to-earnings-growth ratio of 2.21 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last announced its earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. Equities research analysts expect that Alkermes plc will post 1.31 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ALKS has been the topic of several research reports. Stifel Nicolaus raised Alkermes from a “hold” rating to a “buy” rating and lifted their target price for the stock from $25.00 to $36.00 in a report on Tuesday, November 5th. HC Wainwright reaffirmed a “neutral” rating and issued a $46.00 target price on shares of Alkermes in a report on Thursday, February 13th. Mizuho lifted their target price on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. StockNews.com raised Alkermes from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 13th. Finally, The Goldman Sachs Group boosted their price objective on Alkermes from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.36.

Insider Buying and Selling at Alkermes

In related news, SVP Christian Todd Nichols sold 5,208 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total value of $151,813.20. Following the completion of the sale, the senior vice president now owns 60,703 shares in the company, valued at approximately $1,769,492.45. The trade was a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Cato T. Laurencin sold 2,691 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $31.85, for a total value of $85,708.35. Following the completion of the sale, the director now owns 23,013 shares of the company’s stock, valued at $732,964.05. The trade was a 10.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 323,608 shares of company stock worth $10,854,725 over the last 90 days. Company insiders own 4.89% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.